Evidence map›Paper›PMID 32878499›Full record

ReviewCritical reviews in biochemistry and molecular biology2020

Fragile X-related protein family: a double-edged sword in neurodevelopmental disorders and cancer.

Mrinmoyee Majumder, Roger H Johnson, Viswanathan Palanisamy

Open access · greenAbstract readReview
In one paragraph

Review in Critical reviews in biochemistry and molecular biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 41 citations in OpenAlex.

  1. FMRP promotes gastric cancer progression via mJournal of translational medicine · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Mrinmoyee MajumderDepartment of Biochemistry and Molecular Biology, School of Medicine, Medical University of South Carolina, Charleston, SC, USA.
Roger H JohnsonHollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Viswanathan PalanisamyDepartment of Biochemistry and Molecular Biology, School of Medicine, Medical University of South Carolina, Charleston, SC, USA.ORCID 0000-0001-5128-2878
Medical University of South Carolina · US

Funding

Comprehensive Identification of FXR1 Targets Using pSILAC-BONCAT ProteomicsR21DE025920 · NIDCR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PALANISAMY, VISWANATHAN · 2017 to 2018
$411k
NIDCR NIH HHS R21 DE025920
6 · The paper itself

Abstract

The fragile X-related (FXR) family proteins FMRP, FXR1, and FXR2 are RNA binding proteins that play a critical role in RNA metabolism, neuronal plasticity, and muscle development. These proteins share significant homology in their protein domains, which are functionally and structurally similar to each other. FXR family members are known to play an essential role in causing fragile X mental retardation syndrome (FXS), the most common genetic form of autism spectrum disorder. Recent advances in our understanding of this family of proteins have occurred in tandem with discoveries of great importance to neurological disorders and cancer biology

Indexed as

Fragile X Messenger Ribonucleoprotein 1Fragile X SyndromeHumansMutationNeoplasmsNeurodevelopmental DisordersRNA-Binding ProteinsFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1FXR1 protein, humanFXR2 protein, humanRNA-Binding ProteinscancerFMRPfragile X mental retardation syndromeFXR1FXR2post-transcriptional gene regulationpost-translational protein modificationprotein domainsRNA binding

Identifiers

PMID32878499
PMCPMC7695039
OpenAlexW3082160583

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.